Business
Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas
Clinically meaningful response in difficult to treat type of CTCL PRINCETON, N.J., Feb. 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or
About this update from Soligenix, Inc.
[{"type":"text","content":"Clinically meaningful response in difficult to treat type of CTCL\n\n\nPRINCETON, N.J., Feb. 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Brian Poligone, clinical investigator and lead enroller in the pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study evaluating SGX301 in the treatment of early stage cutaneous T-cell lymphoma (CTCL), will present a patient case study from the trial. The presentation will be given at the upcoming 4th World Congress of Cutaneous Lymphomas on February 12-14, in Barcelona, Spain.\nOral Presentation: \nResponse in a patient with refractory folliculotropic mycosis fungoides to a topical hypericin ointment activated with fluorescent light presented by Brian Poligone, MD, PhD, an Investigator in the FLASH study and Director of the Rochester Skin Lymphoma Medical Group, Fairport, NY, USA, on February 13th, 2020 at 8:00 AM CET. Abstract will be available on corporate website following the conference.\nFolliculotropic mycosis fungoides (FMF) is a type of CTCL that is very difficult to treat. FMF is generally considered more severe and aggressive than other types of CTCL due to its greater risk of disease progression and worse prognosis. Treatment usually includes early consideration of systemic therapies, as topical therapies are often not beneficial. The presented case study focuses on a single patient with FMF who has completed the Phase 3 FLASH trial, including the open-label cycles and 6-month follow-up. The patient had previously failed at least five therapies, including topical treatments, oral medications and phototherapy. While in the study, the patient received at least 12 weeks of SGX301 treatment and experienced significant improvement, eventually leading to complete clearance of disease that has been sustained for at least 4 years. \n\"I'm happy to be presenting this important case study at the world congress,\" stated Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Group. \"This patient community needs safe, skin directed therapies to treat this difficult lymphoma and I'm very excited that SGX301 may be one such therapy. I know I can speak for ...